Cogent Biosciences (COGT) Stock Forecast & Price Prediction

Estimation of the future price movement of Cogent Biosciences stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target

Current $8.63

Concensus $20.33

Low $15.00

Median $22.00

High $24.00

Based on analysts projections #COGT is expected to experience a positive growth trajectory over the next year.

The current average COGT price target, as estimated by these analysts, is $20.33.

The predictions for the future COGT stock price range from a low of $15.00 to a high of $24.00, highlighting the variability of market expectations for COGT.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

COGT stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Needham December 14, 2022 Buy 24.00 12.32
Chris Raymond
Raymond James
June 17, 2022 Buy 22.00 9.19
Christopher Liu
Leerink Partners
June 10, 2022 Buy 15.00 10.74

Cogent Biosciences (COGT) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if Cogent Biosciences is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.


Financial Scores

Updated on: 06/12/2023

Altman Z-Score: 4.8

Piotroski Score: 2.0

ESG Score

Updated on: 06/12/2023

Environmental: 41.7

Social: 65.9

Governance: 70.9

Financial Health

Updated on: 06/12/2023

DCF: Strong Buy

ROE: Sell

ROA: Sell

Debt to equity ratio: Neutral

Price to earnings ratio: Strong Sell

Price to book ratio: Strong Buy

COGT Discounted Cash Flow

Updated on: 06/12/2023

Discounted Cash Flow Value

Current Price

COGT Revenues by Segment

Updated on: 06/12/2023

Preclinical Research And Clinical Development

Revenue from Contract with Customer, Excluding Assessed Tax

COGT Revenues by Region

Updated on: 06/12/2023

No available data

COGT Notes Due

Updated on: 06/12/2023


There are no data to display

Cogent Biosciences (COGT) Social Sentiments

Monitoring bullish and bearish sentiments towards Cogent Biosciences on Twitter and Stocktwits could help to forecast an upward or downward trend in Cogent Biosciences stock price.

Analyzing COGT Stock Forecast: Cogent Biosciences' Precision Therapy for Rare Genetic Diseases

Cogent Biosciences, whose stock ticker is COGT, is a biotechnology company that focuses on developing precision therapies for patients. Their research and development programs focus on the treatment of genetic diseases such as X-linked Hypophosphatemia (XLH), Genetic Epilepsies, and Charcot-Marie-Tooth (CMT) disease. Cogent Biosciences has already made significant strides in the field of genetic diseases. The company's lead candidate, CGT9486,... Read more

Cogent Biosciences Stock Prediction: Analyzing the Potential for High Returns in the Biotech Sector

The biotechnology sector is one of the most exciting and dynamic markets in the investment world. Biotech companies are focused on developing groundbreaking treatments for various diseases, ranging from cancer to genetic disorders. As such, investors often look to this sector for high potential returns. One company worth examining when analyzing the biotechnology stock market is Cogent Biosciences (ticker: COGT)....
However, when looking at predictions for Cogent Biosciences' stock performance both prior to and after it has released its trail data, there is always some inherent uncertainty involved with investments in early-stage biotech companies. Unlike more established firms like Pfizer or Merck with their extensive product lines and healthy revenue streams that can absorb setbacks along the way, small-cap stocks like COGT may experience far more pronounced swings based upon market uncertainty surrounding a potentially effective drug candidate.

Investing in biotech stocks requires patience and deep research. Investors need to remain up-to-date with key developments from companies such as Cogent Biosciences by closely following scientific publications regarding successes – or failures – related to their drug pipelines along with equity analyst insights who might provide additional context around such events.

In conclusion, while preclinical results look promising, Cogent Biosciences will need to present strong trial results or more compelling data on its work for stockholders to find enough of an argument to invest in this high-potential stock. Therefore, it could be appropriate for investors who are willing and comfortable with having a substantial amount of risk within their portfolio to explore the outcome of this clinical testing closer. As always, consulting a financial advisor beforehand can help individual investors better manage their asset allocations in deciding whether or not COGT represents an appealing opportunity within the biotech arena.">Read more